Rechercher des projets européens

12 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Translating disease to cardiovascular health (TransCard)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Cardiovascular disease (CVD) is the leading cause of death in Europe and the world. Drugs that lower cholesterol in blood are the most efficient drugs used to date but we are currently still facing a 50-70% residual risk of suffering from CVD. This clearly illustrates an urgent need for the identification, characterization and validation of novel therapeutically relevant targets. Over the last dec ...
Voir le projet

 8

 TERMINÉ 
"Through combining basic pre-clinical and clinical research, network analysis and computational modelling, RESOLVE aims at resolving the disturbed dynamics and mechanisms underlying the high triglyceride (HTG) and low high-density lipoprotein cholesterol (HDL-C) phenotype and insulin resistance in patients with metabolic syndrome (MetS) and its associated co-morbidities (cardiovascular disease, CV ...
Voir le projet

 14

 TERMINÉ 

VitaminD3-Omega3-Home Exercise- HeALTHy Ageing and Longevity Trial (DO-HEALTH)

Date du début: 1 janv. 2012, Date de fin: 30 juin 2017,

As the European population is ageing rapidly, the growing number of seniors with age-related chronic diseases poses a challenge on European societies and health care systems. Therapeutic interventions that are effective, affordable and well-tolerated in the prevention of chronic disease are urgently needed and will have an outstanding impact on public health as a whole. Among the most promising in ...
Voir le projet

 25

 TERMINÉ 

DARPin Targeted Magnetic Hyperthermic Therapy for Glioblastoma (DARTRIX)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

"DARTRIX, ‘DARPin Targeted RX (therapy)’ is a multidisciplinary collaborative project that will develop high-affinity protein scaffolds to create a new generation of targeted therapeutics for the treatment of glioblastoma. There is great need; glioblastoma is virtually incurable and most patients die within 12 months of diagnosis. DARPins are small, non-immunoglobulin human protein scaffolds that ...
Voir le projet

 8

 TERMINÉ 
SeaBioTech is a 48-month project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical (human and aquaculture), cosmetic, functional food and industrial chemistry sectors. SeaBioTech will reduce barriers to successful industrial exploitation of marine biodivers ...
Voir le projet

 17

 TERMINÉ 
"Cancer is a complex disease involving multiple genetic and epigenetic events occurring, and influencing each other, over a long period of time. Understanding cancer, and ultimately developing effective targeted therapies, will therefore require that mutations and epigenetic alterations be systematically investigated during the multiple stages of disease development, from identifiable pre-neoplast ...
Voir le projet

 18

 TERMINÉ 

Cutaneous and Mucosal HIV Vaccination (CUT'HIVAC)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2015,

Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cel ...
Voir le projet

 18

 TERMINÉ 

INOvative Energy MANagement System for Cargo SHIP (INOMANS²HIP)

Date du début: 1 mai 2011, Date de fin: 30 nov. 2015,

The global optimization of energy systems aboard future and currently operating cargos is crucial to reduce greenhouse gas emission in a substantial and cost effective way. It is also of major economic interest in the merchant marine sector.A holistic approach considering the overall production and management of energy aboard ships (including propulsion systems and energy output optimization) is t ...
Voir le projet

 12

 TERMINÉ 

To decipher the optimal management of systemic sclerosis (DESSCIPHER)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2015,

The current approach to diagnosis and management of the rare disease systemic sclerosis (SSc) is based on American College of Rheumatology criteria with low sensitivity and few validated recommendations for the therapy of the disease and its manifold organ manifestations. To overcome these shortcomings, the DeSScipher project will use the multinational, prospective and open EUSTAR (Scleroderma Tri ...
Voir le projet

 15

 TERMINÉ 

HER Imaging and Molecular Interaction Mapping in Breast Cancer (IMAGINT)

Date du début: 1 mai 2011, Date de fin: 30 avr. 2015,

The aim is to develop tools for imaging and characterising protein/protein and protein/RNA interactions in cancer using Designed Ankyrin Repeat Proteins (DARPins). DARPins are small, ultrahighly stable, antibody-like proteins that bind specific targets with high affinity in monovalent form and are readily engineered for site-specific chemical modification. The exemplar protein family will be EGFR, ...
Voir le projet

 11

 TERMINÉ 

Systems Biology of T-cell Activation in Health and Disease (SYBILLA)

Date du début: 1 avr. 2008, Date de fin: 30 sept. 2013,

T-cell activation, whether induced by pathogens or auto-antigens, is a complex process relying on multiple layers of tightly controlled intracellular signalling modules that form an intricate network. Defects in this network can cause severe and chronic disorders such as autoimmune diseases. Although 5% of the population suffer from these diseases, only a few therapeutic treatments are available. ...
Voir le projet

 22

 TERMINÉ 

Persisting Transgenesis (PERSIST)

Date du début: 1 janv. 2009, Date de fin: 30 juin 2013,

"For many disabling or fatal diseases, there is pre-clinical or clinical evidence of the potential therapeutic efficacy of gene therapy and, yet, the limitations of current gene transfer technologies have prevented success or even caused serious adverse events leading to termination of trials. PERSIST will explore the use of highly innovative gene-modifying and delivery technologies and capitalize ...
Voir le projet

 29